NORTH Trial
A phase II study of Panobinostat in Paediatric, Adolescent and Young Adults with Solid Tumours including Neuroblastoma, Osteosarcoma, Malignant Rhabdoid Tumour/Atypical Teratoid Rhabdoid Tumours
Bone Cancers (Ewing Sarcoma/Osteosarcoma), Brain and other Central Nervous System (CNS) Tumours, Neuroblastoma
Status:
Closed to Recruitment
The purpose of the study is to determine the ability of the drug panobinstat to control the growth of each of the tumour types and to describe the drug’s side effects. The drug is taken orally every day for up to 12 months. The effectiveness of the drug is measured through regular follow ups, including medical imaging.
NORTH is also open at The Preston Robert Tisch Brain Tumor Center at Duke in Durham, North Carolina.
Disease Stage: Relapsed/refractory and limited newly diagnosed
Patient Age Range: <40 years of age
Sample Size: 60
Trial Sponsors:
- National: ANZCHOG in partnership with ANZSA
